98 articles - From Friday Jul 11 2025 to Friday Jul 18 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
| Aliment Pharmacol Ther |
|---|
Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease. Subcutaneous infliximab is associated with high efficacy rates in IBD. Subcutaneous infliximab may offer clinical benefit above the intravenous formulation. This should provide patients and clinicians with confidence in using subcutaneous infliximab in IBD. Further head-to-head trials are needed to confirm the relative efficacy between these formulations. |
| Am J Gastroenterol |
Spectrum of Interstitial Cell of Cajal Deficits in Chronic Gastroduodenal Disorders: Systematic Review and Meta-Analysis. Marked depletion of ICC is a consistent finding in neurogastroduodenal disorders. A spectrum of disease is revealed, with greater depletion associated with delayed emptying. Techniques for clinically defining ICC-driven gastric neuromuscular dysfunction should be prioritized. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis. Patients who achieved disease clearance 8 weeks after ustekinumab induction were more likely to be in long-term clinical, symptomatic and quality of life remission with ustekinumab maintenance treatment than patients who did not. |
Diagnostics of Autoimmune Hepatitis Enabled by Non-Invasive Clinical Proteomics. Clinical proteomic analyses of paired liver-plasma samples from patients with AIH enabled high diagnostic potential. Proteomics may constitute a novel non-invasive diagnostic tool for AIH if validated in larger, age- and sex-matched cohorts. Clinical trial number NCT05335603. |
High-Throughput Viral Integration Detection Reveals Baseline Breakpoints Burden Associated With HBsAg Seroclearance. The duration of NUC treatment, as well as ALT and AST levels, were associated with the level of clonal expansion in virally-suppressed patients. A lower number of breakpoint types at baseline may be related to a higher HBsAg loss rate following Peg-IFN-based treatment and serve as a useful marker in guiding treatment decision-making (NCT02327416). |
Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation. Incidence of infectious events observed between IBD/LTx patients exposed to 'gut-specific' and 'systemic' biologics were similar. Biologic choice should not be influenced by concerns regarding their co-prescription with transplant immunosuppression. Corticosteroid co-therapy at biologic initiation may be associated with more severe infectious events. |
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH. Polypharmacy is common among patients with MASLD. Those with cirrhosis are most affected, and women with cirrhosis are at an even greater risk. Opioid, benzodiazepine, and nonsteroidal anti-inflammatory drug use is prevalent among patients with cirrhosis despite the known associated risks. Frequent medication use for chronic pain in patients with cirrhosis highlights the need for management plans that optimise safety balanced against therapeutic efficacy. |
| Am J Gastroenterol |
Local post-procedural cryoprevention significantly reduces the incidence of post-ERCP pancreatitis: a multicenter randomized controlled trial. Cryoprevention using ice water significantly reduced PEP incidence, demonstrating a safe, effective, and low-cost strategy. This approach offers a practical alternative, where NSAID use is limited. |
PBC-HOPE: A randomized controlled trial of hypnosis and psychoeducation in women with primary biliary cholangitis and fatigue. At 12 weeks, hypnosis and psychoeducation interventions were not associated with a significant reduction in quantitative measures of fatigue associated with PBC. However, the qualitative changes in perceived fatigue associated with these interventions suggest that maintenance sessions could be beneficial in the longer term. |
| Clin Gastroenterol Hepatol |
A novel risk prediction model for hepatocellular carcinoma in MASLD: A multinational, multicenter cohort study. Overweight/obesity or central obesity and pre-diabetes/diabetes with fibrotic burden were significantly associated with the increased HCC risk in MASLD. The MASLD-HCC score may enable physicians to stratify the HCC risk. |
Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Trial. Mirikizumab-treated participants achieved significantly higher rates of BU CMI and remission at W12 and W52, which was associated with better short- and longer-term clinical outcomes. VIVID-1 was registered on ClinicalTrials.gov, NCT03926130. |
Comparative Effectiveness of Empiric Treatment for Helicobacter pylori in a Large, Diverse Population in the United States. In a large, community-based U.S. population, concomitant and bismuth-quadruple therapies had the highest eradication rates for H. pylori for initial treatment without a substantial decline in efficacy over time, while bismuth quadruple was the most successful salvage regimen. History of macrolides or metronidazole use should be reviewed to inform treatment selection. Repeat use of previously prescribed regimens should be avoided. |
Impact of serious infection on mortality of patients with chronic liver disease: a nationwide population-based cohort study. Patients with CLD exhibited a trend of increased mortality dependent on the number of serious infections and the degree of disease severity of CLD ranging from CLD without cirrhosis, compensated cirrhosis, and decompensated cirrhosis. Decompensated cirrhosis has more than three-fold risk of infection than CLD without cirrhosis. |
Interventional radiological management for Budd-Chiari syndrome: a 10-year retrospective, multicenter survey on 997 patients in China. With predominantly IVC-obstruction presented and recanalization used, interventional radiological treatment could achieve a good long-term outcome in Chinese patients with BCS. |
Risk for Metachronous Advanced Neoplasia in Patients with a Modified Definition of Advanced Adenoma: Data from the New Hampshire Colonoscopy Registry. The modified AA groups had a statistically higher risk of a modified AN outcome and a numerically higher CRC risk than the 10-19mm TA group. Future studies should validate these findings and extend them by examining differences in metachronous risk within the 10-19mm TA group. |
| Endosc Int Open |
Internal traction in endoscopic full-thickness resection for gastric subepithelial lesions arising from the muscularis propria: Comparative study. Internal traction using the novel clip-with-spring device could significantly improve safety and efficacy of gastric EFTR in the distal stomach. |
| Endoscopy |
Encapsulation levels rather than elapsed time after the onset of acute pancreatitis are related to clinical outcomes of pancreatic walled-off necrosis. In patients undergoing EUS-guided WON treatment, the encapsulation status, rather than the time elapsed since disease onset, appeared to be associated with clinical outcomes. |
| Gastrointest Endosc |
Endoscopic ultrasonography-guided biliary drainage via the afferent limb using forward-viewing echoendoscope for managing choledochojejunal anastomotic stricture. FVEUS-BD via the afferent limb is an effective and safe rescue method for managing severe choledochojejunal anastomotic strictures. In benign strictures, it offers the potential for achieving a stent-free status and could become a standard approach. |
| Gut |
<i>Helicobacter pylori</i> antibiotic resistance: a global challenge in search of solutions. Background antibiotic resistance requires an urgent revision of current management strategies. Possible solutions include AST-based selection of effective treatment regimens, identification of novel combinations of existing drugs and exploration of novel drugs. |
Therapeutic inhibition of HBsAg and HBV cccDNA through a novel phased combination treatment: glycine and interferon-α. Glycine has the potential to reduce HBV cccDNA levels by stimulating hepatocyte proliferation. The phased administration of glycine and IFN-α significantly enhances its therapeutic efficacy. These findings suggest a novel and promising strategy for the treatment of CHB. |
| Hepatology |
Pretreatment serum bile acid composition and predictability of subsequent response to odevixibat in patients with bile salt export pump (BSEP) deficiency. Higher pretreatment serum levels of unconjugated CA and CDCA are associated with subsequent response to odevixibat in patients with BSEP deficiency. Response to odevixibat may be related to residual biliary bile acid secretion capacity in patients with BSEP deficiency. |
| J Hepatol |
Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled clinical trial. RFX had no beneficial effect in terms of 12-month survival or incidence of complications of liver cirrhosis in patients with severe cirrhosis and low ascitic fluid protein levels. Improving patient adherence could reduce liver complications of cirrhosis. Impact and implications Selective gut decontamination using norfloxacin is the standard of care for secondary prophylaxis of spontaneous bacterial peritonitis (SBP). Evidence for primary prophylaxis of SBP is weaker, and fluoroquinolones have been associated with an increased risk of antimicrobial resistance (AMR). Rifaximin, a well-tolerated broad-spectrum antibiotic with a lower risk of AMR emergence, may be an alternative to norfloxacin. Our trial did not demonstrate an improvement in survival or liver complications (SBP, gastrointestinal bleeding, hepatic encephalopathy or hepatorenal syndrome) at 12 months with rifaximin as primary prophylaxis for SBP versus placebo. However, in the subgroup of patients who adhered to rifaximin, liver complications decreased. Our study highlights the importance of study drug adherence in clinical trials to adequately assess outcomes. Clinical trial number NCT03069131. |
Enhanced surveillance, subtyping, and host adaptation analysis reveal genotype-wide zoonotic potential of rat hepatitis E virus. RHEV shows genotype-wide potential for human spillover infection across its phylogeny. Global surveillance and sequencing efforts of rHEV in humans and rodents are required. Impact and implications Rat hepatitis E virus (rHEV) is an emerging cause of viral hepatitis in humans, but a comprehensive zoonotic assessment is hampered by a lack of sequences and systematic subtyping methods. Using a new, extended dataset of human-derived rHEV strains, we found a wide phylogenetic distribution of human-derived rHEV globally. Regardless of derived host, rHEV codon adaptation was similar for humans, indicating that al rHEV strains should be assumed to have zoonotic potential. Selection analyses revealed that human-derived sequences may be more tolerant to the accumulation of mutations at ORF2, which encodes the viral capsid. Some human-derived strains even showed lower codon usage bias, suggesting that they may have higher survivability and replication across multiple hosts. These results are relevant to clinicians and policymakers as they prove the importance of instituting rHEV surveillance in humans and rodents. |
Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification. We unraveled the intriguing relationship between the mevalonate pathway, CoQ10 production, and selenoprotein translation. The anti-tumor roles of 6-FMEV and atorvastatin highlight the potential of targeting the pathway as a promising therapeutic strategy for HCC. Impact and implications Current treatments show limited efficacy in advanced HCC. This study provides evidence that targeting the mevalonate pathway promotes ferroptosis in HCC by impairing CoQ10 synthesis and selenoprotein translation. Clinically, repurposing atorvastatin or MVD inhibitor 6-FMEV inhibits tumor growth across various HCC subtypes in animal models. Moreover, combining the mevalonate pathway inhibitors with TKIs or ICIs enhances the anti-tumor role, highlighting the translational potential of our study. |
Molecular signatures discriminating different types of rejection in human liver transplants. We report transcriptome features of cAMR that is a unique molecular identity associated with inflammation and fibrogenesis as described in other solid organ transplantations and being linked to a high rate of liver graft failure. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Gastrointest Endosc |
| Gut |
Gut microbiota and atherosclerosis. Interference with the gut microbiota by prebiotics, probiotics and antibiotics has demonstrated beneficial effects on atherosclerosis mainly in preclinical models. Overall, the gut microbiota has appeared as an important rheostat for vascular inflammation in atherosclerosis, which is controlled by host-microbe interactions that may be therapeutically exploited in the future. |
| J Hepatol |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Clin Gastroenterol Hepatol |
| Endoscopy |
| Gastrointest Endosc |
| Gut |
| Hepatology |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Clin Gastroenterol Hepatol |
| Gastroenterology |
| Gastrointest Endosc |
| Gut |
| J Hepatol |